JP2018070559A - Dehydroretinol derivative exhibiting keratin increasing action - Google Patents
Dehydroretinol derivative exhibiting keratin increasing action Download PDFInfo
- Publication number
- JP2018070559A JP2018070559A JP2016215863A JP2016215863A JP2018070559A JP 2018070559 A JP2018070559 A JP 2018070559A JP 2016215863 A JP2016215863 A JP 2016215863A JP 2016215863 A JP2016215863 A JP 2016215863A JP 2018070559 A JP2018070559 A JP 2018070559A
- Authority
- JP
- Japan
- Prior art keywords
- dehydroretinol
- keratin
- derivative
- increasing action
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003042 3-dehydroretinol derivatives Chemical class 0.000 title claims abstract description 31
- 102000011782 Keratins Human genes 0.000 title claims abstract description 31
- 108010076876 Keratins Proteins 0.000 title claims abstract description 31
- 230000001747 exhibiting effect Effects 0.000 title claims abstract description 8
- 230000001965 increasing effect Effects 0.000 title abstract description 11
- 230000009471 action Effects 0.000 claims description 7
- XWCYDHJOKKGVHC-UHFFFAOYSA-N Vitamin A2 Chemical compound OCC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C XWCYDHJOKKGVHC-UHFFFAOYSA-N 0.000 abstract description 16
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 235000007164 Oryza sativa Nutrition 0.000 abstract description 11
- 235000009566 rice Nutrition 0.000 abstract description 11
- 239000002537 cosmetic Substances 0.000 abstract description 9
- DPRNENKPXAZQBI-UHFFFAOYSA-N alpha-Vitamin A Natural products OCC=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C DPRNENKPXAZQBI-UHFFFAOYSA-N 0.000 abstract description 8
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 239000004201 L-cysteine Substances 0.000 abstract description 6
- 235000013878 L-cysteine Nutrition 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 229940057059 monascus purpureus Drugs 0.000 abstract description 6
- 241000196324 Embryophyta Species 0.000 abstract description 5
- 210000004927 skin cell Anatomy 0.000 abstract description 5
- 230000004913 activation Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 230000008635 plant growth Effects 0.000 abstract description 3
- 230000037303 wrinkles Effects 0.000 abstract description 2
- 235000008636 Bacillus subtilis subsp natto Nutrition 0.000 abstract 1
- 244000075779 Bacillus subtilis subsp natto Species 0.000 abstract 1
- 244000113306 Monascus purpureus Species 0.000 abstract 1
- 235000002322 Monascus purpureus Nutrition 0.000 abstract 1
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 238000003306 harvesting Methods 0.000 abstract 1
- 239000005445 natural material Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000002904 solvent Substances 0.000 description 19
- 238000000926 separation method Methods 0.000 description 18
- 238000000855 fermentation Methods 0.000 description 16
- 230000004151 fermentation Effects 0.000 description 16
- 239000011347 resin Substances 0.000 description 16
- 229920005989 resin Polymers 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 235000013305 food Nutrition 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 11
- 241000209094 Oryza Species 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 8
- 235000013557 nattō Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 210000004920 epithelial cell of skin Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 244000063299 Bacillus subtilis Species 0.000 description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 235000004347 Perilla Nutrition 0.000 description 4
- 244000124853 Perilla frutescens Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229960003471 retinol Drugs 0.000 description 4
- 235000020944 retinol Nutrition 0.000 description 4
- 239000011607 retinol Substances 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 240000006439 Aspergillus oryzae Species 0.000 description 3
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000003905 agrochemical Substances 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 235000021329 brown rice Nutrition 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 3
- 239000005962 plant activator Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000881711 Acipenser sturio Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OBODKGDXEIUEIH-DAWLFQHYSA-N all-trans-3-hydroxyretinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CC(O)CC1(C)C OBODKGDXEIUEIH-DAWLFQHYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 231100000949 EpiSkin SIT Toxicity 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 231100000950 SkinEthic RHE Toxicity 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000005094 fruit set Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical class [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 235000001508 sulfur Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
Abstract
Description
この発明はケラチン増加作用を呈するデヒドロレチノール誘導体に関するものである。 The present invention relates to a dehydroretinol derivative exhibiting a keratin increasing action.
ケラチンは細胞内骨格を形成するタンパク質であるとともに、皮膚や血管などの組織を構成する硬質のタンパク質であり、骨や皮膚の組織の維持に重要な働きを担っている。また、ケラチンは上皮細胞刺激と細胞の再生により体内で生合成される。 Keratin is a protein that forms an intracellular skeleton and is a hard protein that constitutes tissues such as skin and blood vessels, and plays an important role in maintaining bone and skin tissues. Keratin is biosynthesized in the body by epithelial cell stimulation and cell regeneration.
皮膚に含有されるケラチンは角質の保護、上皮細胞の配列に関与し、美容的には皮膚の皮丘や皮溝の整列や配列にも影響することから、シワや皮膚のたるみとの関係が強い。また、毛髪の維持のためにもケラチンの維持や増加は必須である。 The keratin contained in the skin is involved in the protection of the stratum corneum, the arrangement of epithelial cells, and cosmetically affects the alignment and arrangement of the skin dermis and skin groove, so it has a relationship with wrinkles and sagging skin. strong. In addition, maintenance and increase of keratin are essential for maintaining hair.
さらに、角質化しない上皮細胞においてもケラチンは組織の構成タンパク質として重要な役割を果たしており、上皮組織のシート状構造はケラチン繊維によって機械的強度を保っている。ケラチンの増加をもたらす安全性の高い天然物が望まれている。 Further, keratin plays an important role as a tissue constituent protein even in non-keratinized epithelial cells, and the sheet-like structure of epithelial tissue maintains mechanical strength by keratin fibers. A highly safe natural product that causes an increase in keratin is desired.
例えば、ケラチン繊維の保護剤としての複素環式第4級ポリアンモニウムポリマーの用途及び化粧品用組成物がある(例えば、特許文献1参照)。しかし、その利用範囲は限定的であり、皮膚細胞に直接作用するような強い作用は示されていない。 For example, there is a use of a heterocyclic quaternary polyammonium polymer as a protective agent for keratin fibers and a cosmetic composition (see, for example, Patent Document 1). However, the range of use is limited, and no strong action that directly acts on skin cells has been shown.
既存の植物エキスや化学物質によるケラチン増加作用は軽度であり、産業上への利用が限定されるという課題がある。 The effect of increasing keratin by existing plant extracts and chemical substances is mild, and there is a problem that their industrial use is limited.
また、化学合成された物質では安全性に問題があり、利用が限られている。 In addition, chemically synthesized substances have safety problems and their use is limited.
そこで、副作用が弱く優れたケラチン増加作用を呈する天然物が望まれている。 Therefore, a natural product that exhibits an excellent keratin-increasing action with weak side effects is desired.
上記の目的を達成するために、請求項1に記載の発明は下記の式(1)示されるケラチン増加作用を呈するデヒドロレチノール誘導体に関するものである。 In order to achieve the above object, the invention described in claim 1 relates to a dehydroretinol derivative exhibiting a keratin increasing action represented by the following formula (1).
この発明は、以上のように構成されているため、次のような効果を奏する。 Since this invention is comprised as mentioned above, there exist the following effects.
請求項1に記載のデヒドロレチノール誘導体によれば、副作用が少ないケラチン増加作用を呈する天然物が得られる。 According to the dehydroretinol derivative according to claim 1, a natural product exhibiting a keratin increasing action with few side effects can be obtained.
以下、この発明を具体化した実施形態について詳細に説明する。 Hereinafter, embodiments embodying the present invention will be described in detail.
ケラチン産生作用を呈するデヒドロレチノール誘導体とは以下の式(1)で示される構造からなる。 The dehydroretinol derivative exhibiting a keratin production action has a structure represented by the following formula (1).
ここに示したデヒドロレチノール誘導体は人の皮膚細胞や毛髪細胞に直接作用してケラチン産生を増加させる。その作用には皮膚の上皮細胞の増殖とケラチン産生酵素の誘導が関与している。 The dehydroretinol derivative shown here acts directly on human skin cells and hair cells to increase keratin production. Its action involves the proliferation of skin epithelial cells and the induction of keratinogenic enzymes.
このデヒドロレチノール誘導体はヒドロキシレチノールとL―システインから構成される。分子式はC26H38O3N2S2であり、炭素26個、水素38個、酸素3個、窒素2個及びイオウ2個から構成されている。つまり、ヒドロキシレチノール1分子にL―システインが2分子結合している。 This dehydroretinol derivative is composed of hydroxyretinol and L-cysteine. The molecular formula is C26H38O3N2S2 and is composed of 26 carbons, 38 hydrogens, 3 oxygens, 2 nitrogens and 2 sulfurs. That is, two molecules of L-cysteine are bonded to one molecule of hydroxyretinol.
このデヒドロレチノール誘導体はレチノールとシステインから有機化学的に合成することができ、標準品として構造解析の目的で利用できる。また、ダイヤイオン(三菱化学(株)社製)及びXAD−2またはXAD−4(ロームアンドハース社製)、セファデックスLH−20(アマシャムファルマシア社製)、イオン交換担体IRA−410(ロームアンドハース社製)、逆相担体DM1020T(富士シリシア社製)により精製され、純度95%以上の精製品を得ることができる。 This dehydroretinol derivative can be synthesized organically from retinol and cysteine, and can be used as a standard product for the purpose of structural analysis. Diaion (Mitsubishi Chemical Corporation) and XAD-2 or XAD-4 (Rohm and Haas), Sephadex LH-20 (Amersham Pharmacia), ion exchange carrier IRA-410 (Rohm and) Purified product by reverse phase carrier DM1020T (manufactured by Fuji Silysia), and a purified product having a purity of 95% or more can be obtained.
この構造は核磁気共鳴装置(例えば、NMR、ブルカー製)により、CD3OD中における1H−NMRと13C−NMRの解析を行うことにより解析される。600MHzの1H−NMR解析により、1.469、1.514、1.661、1.887、1.955、2.079、2.102、2.124、2.192、2.215、2.305、2.407、2.565、2.599、2.644、2.667、2.712、2.893、3.040、3.254、3.367、3.763、4.023、4.068、5.119、6.147、6.283、7.006及び7.379ppmにピークが認められる。 This structure is analyzed by analyzing 1H-NMR and 13C-NMR in CD3OD with a nuclear magnetic resonance apparatus (for example, NMR, manufactured by Bruker). 1.469, 1.514, 1.661, 1.887, 1.955, 2.079, 2.102, 2.124, 2.192, 2.215, 2.600 by 1H-NMR analysis at 600 MHz. 305, 2.407, 2.565, 2.599, 2.644, 2.667, 2.712, 2.893, 3.040, 3.254, 3.367, 3.763, 4.023, Peaks are observed at 4.068, 5.119, 6.147, 6.283, 7.006, and 7.379 ppm.
さらに、CD3OD中13C−NMRの解析により、23.0、26.7、27.1、27.3、28.7、30.0、34.1、39.9、41.6、46.7、49.4、51.6、55.3、58.8、71.8、72.6、78.8、129.6、135.1、141.0、142.5及び176.2ppmにピークが認められる。 Furthermore, by analysis of 13C-NMR in CD3OD, 23.0, 26.7, 27.1, 27.3, 28.7, 30.0, 34.1, 39.9, 41.6, 46.7 49.4, 51.6, 55.3, 58.8, 71.8, 72.6, 78.8, 129.6, 135.1, 141.0, 142.5 and 176.2 ppm. Is recognized.
デヒドロレチノールとはカロテノイドの一種であり、抗酸化作用や視神経に対する働きがあり、皮膚に対しても細胞の増殖と維持に働く天然物である。自然界ではデヒドロレチノールはレチノールから酵素により産生され、生体内で分解され、排泄されることから安全性が高い。また、体内や環境中での蓄積性は認められず、環境への安全性も高い。 Dehydroretinol is a kind of carotenoid, a natural product that has an antioxidant effect and an action on the optic nerve, and also works on the proliferation and maintenance of cells on the skin. In nature, dehydroretinol is highly safe because it is produced from retinol by an enzyme, decomposed in vivo, and excreted. In addition, accumulation in the body and environment is not recognized, and safety to the environment is high.
ここで示したデヒドロレチノール誘導体はデヒドロレチノールの水酸基とL−システインのカルボキシル基がエステル結合している。また、イオン化しやすいことから皮膚への吸収や腸管からの吸収にも優れている。また、このデヒドロレチノール誘導体にはケラチンの構成成分となるL―システインが存在するため、ケラチンの原料としても有用である。 The dehydroretinol derivative shown here has an ester bond between the hydroxyl group of dehydroretinol and the carboxyl group of L-cysteine. Moreover, since it is easily ionized, it is excellent in absorption into the skin and absorption from the intestinal tract. In addition, since this dehydroretinol derivative contains L-cysteine, which is a constituent component of keratin, it is also useful as a raw material for keratin.
さらに、このデヒドロレチノール誘導体は皮膚の上皮細胞の上皮細胞増殖因子の受容体を活性化する。活性化の方法は感度の向上であり、いわゆる、ハイパーセンシティビティであり、酵素の活性中心に働き、触媒としての感受性を高める。 In addition, this dehydroretinol derivative activates the epidermal growth factor receptor in skin epithelial cells. The activation method is an improvement in sensitivity, which is so-called hypersensitivity, works on the active center of the enzyme, and increases the sensitivity as a catalyst.
このデヒドロレチノール誘導体の過剰量は肝臓や腎臓に存在している非特異的なエステラーゼにより分解され、デヒドロレチノールとL―システインに分解される。 The excessive amount of the dehydroretinol derivative is degraded by non-specific esterase present in the liver and kidney, and is degraded into dehydroretinol and L-cysteine.
デヒドロレチノールとL―システインはいずれも天然界に存在しており、安全性も確認されていることから、このデヒドロレチノール誘導体の安全性は高い。 Since dehydroretinol and L-cysteine both exist in nature and safety has been confirmed, the safety of this dehydroretinol derivative is high.
また、このデヒドロレチノール誘導体は脂肪に蓄積されることはなく、濃縮もされない。 In addition, this dehydroretinol derivative is not accumulated in fat and is not concentrated.
さらに、このデヒドロレチノール誘導体は皮膚の上皮細胞や毛母細胞を増殖させ、ケラチンの産生を増加させる他にも、血流の改善作用、デトックス作用、排泄作用及び代謝活性化作用を有する。 Further, this dehydroretinol derivative proliferates epithelial cells and hair matrix cells of the skin and increases the production of keratin, and also has an effect of improving blood flow, detoxification, excretion and metabolic activation.
このデヒドロレチノール誘導体の製造方法としては、有機化学的に合成する方法の他に、キャビアや野菜類、藻類を発酵して得ることが可能である。 As a method for producing this dehydroretinol derivative, caviar, vegetables, and algae can be fermented in addition to the organic chemical synthesis method.
このうち、キャビアには豊富なレチノールが含有され、さらに、皮膚細胞や毛母細胞の増殖を促進する上皮細胞増殖因子が含有されていることから好ましい。キャビアとは学名Acipenser medirostrisであるチョウザメの卵である。塩漬けされた状態でもレチノールには影響しないことから、塩漬けされたキャビアでも利用できる。 Among these, caviar is preferable because it contains abundant retinol and further contains an epidermal growth factor that promotes the growth of skin cells and hair matrix cells. Caviar is a sturgeon egg with the scientific name Acipeser medirostris. Since it does not affect retinol even in the salted state, it can also be used in salted caviar.
この発酵の工程は納豆菌、紅麹菌を添加して発酵させる工程からなる。 This fermentation process consists of adding natto and red yeast and fermenting them.
次に納豆菌と紅麹菌により発酵される。すなわち、清浄な発酵タンクにキャビア、コメヌカ、納豆菌と紅麹菌を添加し、好気下で発酵される。 Next, it is fermented with natto and red yeast. That is, caviar, rice bran, natto and red yeast are added to a clean fermentation tank and fermented under aerobic conditions.
原料となるコメヌカは、日本産、中国産、アメリカ産、ロシア産などいずれの産地の玄米から得られるコメヌカでも利用できるが、トレーサビリティーが確実であり、生産者が明確である日本産が好ましい。このうち、有機栽培や無農薬で栽培された玄米由来のコメヌカは有害な農薬や金属を含有しないことから、さらに好ましい。 The rice bran that can be used as a raw material can be rice bran obtained from brown rice in any production area such as Japanese, Chinese, American and Russian. However, it is preferable that it is traceable and has a clear producer. Among these, rice bran derived from brown rice grown organically or without agricultural chemicals is more preferable because it does not contain harmful agricultural chemicals or metals.
コメヌカは使用に際して、株式会社奈良機械製作所製の自由ミル、スーパー自由ミル、サンプルミル、ゴブリン、スーパークリーンミル、マイクロス、減圧乾燥機として東洋理工製の小型減圧乾燥機、株式会社マツイ製の小型減圧伝熱式乾燥機DPTH−40、エーキューエム九州テクノス株式会社製のクリーンドライVD−7、VD−20、中山技術研究所製DM−6などの粉砕機で粉砕される。この粉砕により発酵の工程が効率的に進行しやすいことから好ましい。 In use, KOMENUKA is a free-form mill, super-free mill, sample mill, goblin, super-clean mill, micros, vacuum dryer from Toyo Riko Co., Ltd. It is pulverized by a pulverizer such as a vacuum heat transfer dryer DPTH-40, clean dry VD-7, VD-20 manufactured by AKM Kyushu Technos Co., Ltd., DM-6 manufactured by Nakayama Technical Research Institute. This pulverization is preferable because the fermentation process easily proceeds efficiently.
用いる納豆菌は学名Bacillus subtilisで日本では納豆の製造や食品加工に汎用され、食経験が豊富で有用な食用菌である。沖縄や鹿児島などの日本産、中国や台湾の東南アジア原産の菌種が用いられる。このうち、納豆本舗製の納豆菌は高い発酵性を呈することから好ましい。 The Bacillus subtilis used is the scientific name Bacillus subtilis, which is widely used in the production of natto and food processing in Japan, and is a useful edible fungus with abundant food experience. Bacteria species from Japan such as Okinawa and Kagoshima, and from Southeast Asia such as China and Taiwan are used. Among these, natto bacteria manufactured by Natto Honpo are preferable because they exhibit high fermentability.
用いる紅麹菌は、学名Monascaceaeで、食経験が豊富で有用な食用菌である。沖縄や鹿児島などの日本産、中国や台湾の東南アジア原産の菌種が用いられる。このうち、紅麹本舗製の紅麹菌は高い発酵性を呈することから好ましい。 The red koji mold used is the scientific name Monascacee, and is an edible fungus that is rich in food experience and useful. Bacteria species from Japan such as Okinawa and Kagoshima, and from Southeast Asia such as China and Taiwan are used. Among these, the red koji mold made by Kurisu Honpo is preferable because it exhibits high fermentability.
前記の発酵に関するそれぞれの添加量は、キャビア1重量に対し、コメヌカは0.4〜5重量、納豆菌は0.002〜0.04重量、紅麹菌は0.001〜0.05重量が好ましい。納豆菌と紅麹菌は発酵される前に、前培養することは、発酵の初発時間を短縮し、発酵時間が短縮されることから好ましい。 As for each addition amount related to the fermentation, 0.4 to 5 wt. For rice bran, 0.002 to 0.04 wt. For Bacillus natto, and 0.001 to 0.05 wt. . It is preferable to pre-cultivate natto and red yeast before fermentation, because the initial time of fermentation is shortened and the fermentation time is shortened.
前記の発酵は清浄な培養用タンクで実施され、滅菌された水道水により前記の材料を混合することは好ましい。 The fermentation is carried out in a clean culture tank, and it is preferable to mix the materials with sterilized tap water.
また、この発酵は、35〜48℃に加温され、発酵は4日間から14日間行われる。 Moreover, this fermentation is heated at 35-48 degreeC, and fermentation is performed for 14 days from 4 days.
発酵後、90℃程度の加温により納豆菌と紅麹菌が死滅し、発酵が停止される。この発酵の工程によってデヒドロレチノールが遊離される。次いで、コメヌカからはヒドロキシプロリンが遊離される。 After fermentation, natto and red yeast are killed by heating at about 90 ° C., and the fermentation is stopped. Dehydroretinol is liberated by this fermentation process. Subsequently, hydroxyproline is released from rice bran.
前記の発酵により生成された発酵物は含水エタノールで抽出されることは、生成物を効率良く回収でき、次の工程が実施しやすいことから、好ましい。また、得られた発酵物を超音波破砕処理することは、生成物が分離しやすいことから、好ましい。また、凍結乾燥などにより、濃縮することは、以下の工程が短時間に実施できることから好ましい。 It is preferable that the fermented product produced by the fermentation is extracted with water-containing ethanol because the product can be efficiently recovered and the next step is easily performed. Moreover, since the product is easy to isolate | separate, it is preferable to ultrasonically crush the obtained fermented material. Moreover, it is preferable to concentrate by freeze drying or the like because the following steps can be performed in a short time.
前記の発酵物を分離し、精製することは純度の高い物質として摂取量を減少させることができる点から好ましい。この精製の方法としては、分離用の樹脂などの精製操作を利用することが好ましい。 It is preferable to separate and purify the fermented product from the viewpoint that the intake can be reduced as a highly pure substance. As a purification method, it is preferable to use a purification operation such as a separation resin.
例えば、分離用担体または樹脂により分離され、分取されることは好ましい。分離用担体または樹脂としては、表面が後述のようにコーティングされた、多孔性の多糖類、酸化珪素化合物、ポリアクリルアミド、ポリスチレン、ポリプロピレン、スチレン−ビニルベンゼン共重合体等が用いられる。0.1〜300μmの粒度を有するものが好ましく、粒度が細かい程、精度の高い分離が行なわれるが、分離時間が長い欠点がある。 For example, it is preferably separated and separated by a separation carrier or resin. As the separation carrier or resin, porous polysaccharides, silicon oxide compounds, polyacrylamide, polystyrene, polypropylene, styrene-vinylbenzene copolymers, etc., whose surfaces are coated as described later, are used. Those having a particle size of 0.1 to 300 μm are preferred. The finer the particle size, the higher the accuracy of the separation, but the longer the separation time.
例えば、逆相担体または樹脂として表面が疎水性化合物でコーティングされたものは、疎水性の高い物質の分離に利用される。陽イオン物質でコーティングされたものは陰イオン性に荷電した物質の分離に適している。また、陰イオン物質でコーティングされたものは陽イオン性に荷電した物質の分離に適している。特異的な抗体をコーティングした場合には、特異的な物質のみを分離するアフィニティ担体または樹脂として利用される。 For example, a reverse phase carrier or resin whose surface is coated with a hydrophobic compound is used for separation of a highly hydrophobic substance. Those coated with a cationic substance are suitable for the separation of anionically charged substances. Also, those coated with an anionic substance are suitable for separating a cationically charged substance. When a specific antibody is coated, it is used as an affinity carrier or resin for separating only a specific substance.
アフィニティ担体または樹脂は、抗原抗体反応を利用して抗原の特異的な調製に利用される。分配性担体または樹脂は、シリカゲル(メルク社製)等のように、物質と分離用溶媒の間の分配係数に差異がある場合、それらの物質の単離に利用される。 The affinity carrier or resin is used for specific preparation of an antigen using an antigen-antibody reaction. A partitionable carrier or resin is used for isolation of a substance such as silica gel (manufactured by Merck) if there is a difference in partition coefficient between the substance and the solvent for separation.
これらのうち、製造コストを低減することができる点から、吸着性担体または樹脂、分配性担体または樹脂、分子篩用担体または樹脂及びイオン交換担体または樹脂が好ましい。さらに、分離用溶媒に対して分配係数の差異が大きい点から、逆相担体または樹脂及び分配性担体または樹脂はより好ましい。 Among these, an adsorbent carrier or resin, a dispersible carrier or resin, a molecular sieve carrier or resin, and an ion exchange carrier or resin are preferable from the viewpoint of reducing production costs. Furthermore, the reverse phase carrier or resin and the dispersible carrier or resin are more preferable because the difference in the distribution coefficient with respect to the separation solvent is large.
分離用溶媒として有機溶媒を用いる場合には、有機溶媒に耐性を有する担体または樹脂が用いられる。また、医薬品製造または食品製造に利用される担体または樹脂は好ましい。 When an organic solvent is used as the separation solvent, a carrier or resin having resistance to the organic solvent is used. Moreover, the carrier or resin used for pharmaceutical manufacture or food manufacture is preferable.
これらの点から吸着性担体としてダイヤイオン(HP−20型またはHP21型、三菱化学(株)社製)及びXAD−2またはXAD−4(ロームアンドハース社製)、分子篩用担体としてセファデックスLH−20(アマシャムファルマシア社製)、分配用担体としてシリカゲル、イオン交換担体としてIRA−410(ロームアンドハース社製)、逆相担体としてDM1020T(富士シリシア社製)がより好ましい。 From these points, Diaion (HP-20 or HP21, Mitsubishi Chemical Co., Ltd.) and XAD-2 or XAD-4 (Rohm and Haas) are used as adsorptive carriers, and Sephadex LH is used as a molecular sieve carrier. More preferred is -20 (manufactured by Amersham Pharmacia), silica gel as a carrier for distribution, IRA-410 (manufactured by Rohm and Haas) as an ion exchange carrier, and DM1020T (manufactured by Fuji Silysia) as a reverse phase carrier.
これらのうち、ダイヤイオンHP−20型、セファデックスLH−20及びDM1020Tはさらに好ましい。 Of these, Diaion HP-20, Sephadex LH-20 and DM1020T are more preferred.
得られた抽出物は、分離前に分離用担体または樹脂を膨潤化させるための溶媒に溶解される。その量は、分離効率の点から抽出物の重量に対して1〜35倍量が好ましく、4〜25倍量がより好ましい。分離の温度としては物質の安定性の点から4〜30℃が好ましく、10〜25℃がより好ましい。 The obtained extract is dissolved in a solvent for swelling the carrier for separation or the resin before separation. The amount is preferably 1 to 35 times the weight of the extract from the viewpoint of separation efficiency, and more preferably 4 to 25 times the amount. The separation temperature is preferably 4 to 30 ° C., more preferably 10 to 25 ° C. from the viewpoint of the stability of the substance.
分離用溶媒には、水、または、水を含有する低級アルコール、親水性溶媒、親油性溶媒が用いられる。低級アルコールとしては、メタノール、エタノール、プロパノール、ブタノールが用いられるが、食用として利用されているエタノールが好ましい。 As the separation solvent, water or a lower alcohol containing water, a hydrophilic solvent, or a lipophilic solvent is used. As the lower alcohol, methanol, ethanol, propanol and butanol are used, and ethanol used for food is preferable.
セファデックスLH−20を用いる場合、分離用溶媒には低級アルコールが好ましい。シリカゲルを用いる場合、分離用溶媒にはクロロホルム、メタノール、酢酸またはそれらの混合液が好ましい。 When Sephadex LH-20 is used, a lower alcohol is preferable as the separation solvent. When silica gel is used, the separation solvent is preferably chloroform, methanol, acetic acid or a mixture thereof.
ダイヤイオンHP−20型及びDM1020Tを用いる場合、分離用溶媒はメタノール、エタノール等の低級アルコールまたは低級アルコールと水の混合液が好ましい。 When Diaion HP-20 type and DM1020T are used, the separation solvent is preferably a lower alcohol such as methanol or ethanol or a mixed solution of lower alcohol and water.
また、活性を含む画分を採取して乾燥または真空乾燥により溶媒を除去し、粉末または濃縮液として得ることは溶媒による影響を除外できることから、好ましい。 In addition, it is preferable to collect a fraction containing the activity and remove the solvent by drying or vacuum drying to obtain a powder or a concentrated liquid because the influence of the solvent can be excluded.
また、最終抽出を食用油や化粧料に用いる油脂で実施することは、得られる活性部分が油の中で安定に維持することから好ましい。例えば、大豆油、米ぬか油、グレープシード油、オリーブ油、ホホバ油で抽出することは好ましい。 Moreover, it is preferable to carry out the final extraction with fats and oils used for edible oils and cosmetics because the obtained active part is stably maintained in the oil. For example, extraction with soybean oil, rice bran oil, grape seed oil, olive oil or jojoba oil is preferred.
医薬品として注射剤または経口剤または塗布剤などの非経口剤として利用され、医薬部外品としては、錠剤、カプセル剤、ドリンク剤、石鹸、塗布剤、ゲル剤、歯磨き粉等に配合されて利用される。 It is used as an injectable or parenteral agent such as an oral agent or a coating agent as a pharmaceutical, and as a quasi-drug, it is used in a tablet, capsule, drink, soap, coating agent, gel, toothpaste, etc. The
経口剤としては錠剤、カプセル剤、散剤、シロップ剤、ドリンク剤等が挙げられる。前記の錠剤及びカプセル剤に混和される場合には、結合剤、賦形剤、膨化剤、滑沢剤、甘味剤、香味剤等とともに用いることができる。前記の錠剤は、シェラックまたは砂糖で被覆することもできる。 Examples of oral preparations include tablets, capsules, powders, syrups, and drinks. When mixed with the above-mentioned tablets and capsules, it can be used together with a binder, excipient, swelling agent, lubricant, sweetener, flavoring agent and the like. The tablets can also be coated with shellac or sugar.
また、前記のカプセル剤の場合には、上記の材料にさらに油脂等の素材を含有させることができる。前記のシロップ剤及びドリンク剤の場合には、甘味剤、防腐剤、色素香味剤等を添加することができる。 Moreover, in the case of the said capsule, raw materials, such as fats and oils, can be further contained in said material. In the case of the above syrup and drink, sweeteners, preservatives, pigment flavoring agents and the like can be added.
非経口剤としては、軟膏剤、クリーム剤、水剤等の外用剤の他に、注射剤が挙げられる。外用剤の基材としては、ワセリン、パラフィン、油脂類、ラノリン、マクロゴールド等が用いられ、通常の方法によって軟膏剤やクリーム剤等とすることができる。 Examples of parenteral preparations include injections in addition to external preparations such as ointments, creams, and liquids. Vaseline, paraffin, fats and oils, lanolin, macro gold, etc. are used as a base material for external preparations, and can be made into ointments, creams, and the like by ordinary methods.
注射剤には、液剤があり、その他、凍結乾燥剤がある。これは使用時、注射用蒸留水や生理食塩液等に無菌的に溶解して用いられる。 Injections include liquids, and other lyophilization agents. This is used aseptically dissolved in distilled water for injection or physiological saline at the time of use.
食品製剤として美容を目的とした美容食品、美容を目的とした食品、肝臓細胞の維持を目的とした滋養強壮剤などに利用される。また、保健機能食品として、栄養機能食品や特定保健用食品に利用することは好ましい。 As a food preparation, it is used in beauty foods for beauty purposes, foods for beauty purposes, and nourishing tonics for the purpose of maintaining liver cells. Moreover, as a health functional food, it is preferable to use it for a nutrition functional food or a food for specified health.
得られた食品製剤をイヌやネコなどのペットや家畜動物に利用する場合、皮膚の健康を維持する目的として、飼料やサプリメントとして利用される。 When the obtained food preparation is used for pets such as dogs and cats and livestock animals, it is used as feed or supplement for the purpose of maintaining skin health.
化粧料として常法に従って界面活性化剤、溶剤、増粘剤、賦形剤等とともに用いることができる。例えば、クリーム、毛髪用ジェル、洗顔剤、美容液、化粧水等の形態とすることができ、ケラチン産生を促進する化粧料となる。化粧料の形態は任意であり、溶液状、クリーム状、ペースト状、ゲル状、ジェル状、固形状または粉末状として用いることができる。 As a cosmetic, it can be used together with a surfactant, a solvent, a thickener, an excipient and the like according to a conventional method. For example, it can be in the form of cream, hair gel, facial cleanser, cosmetic liquid, lotion, etc., and becomes a cosmetic that promotes keratin production. The form of the cosmetic is arbitrary, and can be used as a solution, cream, paste, gel, gel, solid or powder.
また、植物活性化剤として植物の骨格を形成するケラチンを増加させる機序により植物を元気に活性化させる用途にも使用できる。豆類、穀物、米類、根菜類や花にも使用でき、植物のケラチンを増加させて収穫高や品質を高め、植物の生育と寿命を高める。切り花の保持にも利用できる。 Moreover, it can be used also for the use which activates a plant energetically by the mechanism which increases the keratin which forms the skeleton of a plant as a plant activator. It can also be used in beans, cereals, rice, root vegetables and flowers, increasing plant keratin to increase yield and quality and increase plant growth and life. Can also be used to hold cut flowers.
以下、前記実施形態を実施例及び試験例を用いて具体的に説明する。なお、これらは一例であり、素材、原料や検体の違いに応じて常識の範囲内で条件を変更させることが可能である。 Hereinafter, the embodiment will be specifically described with reference to examples and test examples. These are merely examples, and conditions can be changed within the range of common sense according to differences in materials, raw materials, and specimens.
岡山県産の養殖チョウザメより採取されたキャビアを購入して用いた。この450gをミキサーで攪拌した。 Caviar collected from cultured sturgeon from Okayama Prefecture was purchased and used. 450 g of this was stirred with a mixer.
得られたキャビア懸濁液を清浄な発酵タンク(大脇エンジニア製、150kg容量)に入れた。 The obtained caviar suspension was put into a clean fermentation tank (Owaki Engineer, 150 kg capacity).
秋田県産の減農薬栽培玄米より得られた米糠1.1kgを購入し、水道水9Lに懸濁した。この米糠懸濁液をオートクレーブ(トミー精巧製、SR−240)に入れて121℃で滅菌した。 1.1 kg of rice bran obtained from brown rice with reduced agricultural chemicals produced in Akita Prefecture was purchased and suspended in 9 L of tap water. This rice bran suspension was placed in an autoclave (Tomy Seisakusho, SR-240) and sterilized at 121 ° C.
滅菌後、冷却した米糠液を発酵タンクに移し、納豆本舗製の納豆菌8g及紅麹菌10gを添加し、37℃で4日間発酵させた。 After sterilization, the cooled rice bran liquid was transferred to a fermentation tank, and 8 g of natto bacteria and 10 g of red koji molds manufactured by Natto Honpo were added and fermented at 37 ° C. for 4 days.
発酵液を91℃の加温槽に入れて14分間加温し、滅菌させた。これを冷却後、ろ過してろ液8.1Lを得た。これをデヒドロレチノール誘導体含有エキスとした。使用まで、4℃に保管した。 The fermented liquid was put into a 91 degreeC heating tank, was heated for 14 minutes, and was sterilized. This was cooled and then filtered to obtain 8.1 L of filtrate. This was designated as a dehydroretinol derivative-containing extract. Stored at 4 ° C. until use.
前述のデヒドロレチノール誘導体含有エキスの4Lに5%エタノール含有精製水3Lを添加し、ダイヤイオンHP−20型(三菱化学製)200gを4%エタノール液に懸濁して充填したカラムに供した。 3 L of 5% ethanol-containing purified water was added to 4 L of the above-described dehydroretinol derivative-containing extract, and 200 g of Diaion HP-20 type (Mitsubishi Chemical) was suspended in a 4% ethanol solution and packed in a column.
これに3Lの4%エタノール液を添加して清浄し、さらに、40%エタノール液を2L添加して目的とするデヒドロレチノール誘導体を溶出させた。精製されたデヒドロレチノール誘導体を減圧蒸留により、エタノール部分を除去し、水溶液とした。さらに、この精製工程を3回繰り返し、97.3%の純度を示すデヒドロレチノール誘導体の検体1とした。この検体1はHPLCによる分析で単一ピークを呈した。 To this, 3 L of 4% ethanol solution was added for cleaning, and then 2 L of 40% ethanol solution was added to elute the desired dehydroretinol derivative. The ethanol portion was removed from the purified dehydroretinol derivative by distillation under reduced pressure to obtain an aqueous solution. Further, this purification process was repeated three times to obtain a sample 1 of a dehydroretinol derivative having a purity of 97.3%. This specimen 1 exhibited a single peak by HPLC analysis.
以下にデヒドロレチノール誘導体の同定試験について説明する。
(試験例1)
The identification test of the dehydroretinol derivative will be described below.
(Test Example 1)
上記のように得られた実施例1のデヒドロレチノール誘導体である検体1を精製エタノールに溶解し、質量分析器付き高速液体クロマトグラフィ(HPLC、島津製作所)で分析し、さらに、核磁気共鳴装置(NMR、ブルカー製)で解析した。 The specimen 1 which is the dehydroretinol derivative of Example 1 obtained as described above was dissolved in purified ethanol, analyzed by high performance liquid chromatography with a mass spectrometer (HPLC, Shimadzu Corporation), and further a nuclear magnetic resonance apparatus (NMR , Manufactured by Bruker).
その結果、CD3OD中における600MHzの1H−NMR解析により、1.469、1.514、1.661、1.887、1.955、2.079、2.102、2.124、2.192、2.215、2.305、2.407、2.565、2.599、2.644、2.667、2.712、2.893、3.040、3.254、3.367、3.763、4.023、4.068、5.119、6.147、6.283、7.006及び7.379ppmにピークが認められた。 As a result, by 1H-NMR analysis at 600 MHz in CD3OD, 1.469, 1.514, 1.661, 1.887, 1.955, 2.079, 2.102, 2.124, 2.192, 2.215, 2.305, 2.407, 2.565, 2.599, 2.644, 2.667, 2.712, 2.893, 3.040, 3.254, 3.367, 3. Peaks were observed at 763, 4.023, 4.068, 5.119, 6.147, 6.283, 7.006 and 7.379 ppm.
さらに、CD3OD中13C−NMRの解析により、23.0、26.7、27.1、27.3、28.7、30.0、34.1、39.9、41.6、46.7、49.4、51.6、55.3、58.8、71.8、72.6、78.8、129.6、135.1、141.0、142.5及び176.2ppmにピークが認められた。 Furthermore, by analysis of 13C-NMR in CD3OD, 23.0, 26.7, 27.1, 27.3, 28.7, 30.0, 34.1, 39.9, 41.6, 46.7 49.4, 51.6, 55.3, 58.8, 71.8, 72.6, 78.8, 129.6, 135.1, 141.0, 142.5 and 176.2 ppm. Was recognized.
以下に、13C−NMRの解析結果のチャートを示した。(横軸単位はppm、縦軸単位はピーク強度を示す。)
The chart of the analysis result of 13C-NMR is shown below. (The horizontal axis represents ppm, and the vertical axis represents peak intensity.)
つまり、実施例1の検体は有機化学的に合成し精製された標準品と同一の分析結果を示した。目的とするデヒドロレチノール誘導と同定された。 That is, the sample of Example 1 showed the same analysis results as a standard product synthesized and purified organically. The target dehydroretinol induction was identified.
以下に、ヒト皮膚上皮細胞を用いた確認試験について述べる。
(試験例2)
The confirmation test using human skin epithelial cells is described below.
(Test Example 2)
クラボウ株式会社より購入したヒト皮膚上皮細胞を用いた。培養液としては、5%牛胎児血清含有MEM培地(Sigma製)を用いて培養した、1000個の細胞を35mm培養シャーレに播種し、5%炭酸ガス下、37℃で培養した。これに、前記の実施例1で得られた検体1及び対照として皮膚上皮細胞成長因子(EGF)を0.1mg/mlの最終濃度で添加した。これを48時間培養した。EGFは皮膚の上皮細胞を増殖させ、ケラチンを産生させる生理物質として利用されている。細胞を剥離後、細胞数を計数した。なお、シャーレは5枚を用いてその平均値を算出した。 Human skin epithelial cells purchased from Kurabo Industries Co., Ltd. were used. As a culture solution, 1000 cells cultured using 5% fetal calf serum-containing MEM medium (manufactured by Sigma) were seeded in a 35 mm culture dish, and cultured at 37 ° C. under 5% carbon dioxide gas. To this, specimen 1 obtained in Example 1 and skin epidermal growth factor (EGF) as a control were added at a final concentration of 0.1 mg / ml. This was cultured for 48 hours. EGF is used as a physiological substance for proliferating skin epithelial cells and producing keratin. After detaching the cells, the number of cells was counted. In addition, the petri dish calculated the average value using five sheets.
その結果、検体1の0.1mg/mlの添加により皮膚の上皮細胞数が溶媒対照群に比して平均値として255%に増加した。また、ケラチン量をELISAキット(和光純薬製)により定量した結果、溶媒対照群に比して平均値で344%になった。 As a result, the addition of 0.1 mg / ml of Sample 1 increased the number of skin epithelial cells to 255% as an average value compared to the solvent control group. Moreover, as a result of quantifying the amount of keratins using an ELISA kit (manufactured by Wako Pure Chemical Industries, Ltd.), the average value was 344% compared to the solvent control group.
また、対照としたEGFでは細胞数が対照群に比して181%となった。また、産生されたケラチン量は210%となり、検体1の方がケラチン量の増加に優れていた。 In the EGF as a control, the number of cells was 181% compared to the control group. The amount of keratin produced was 210%, and Sample 1 was superior in increasing the amount of keratin.
一方、安全性試験の一環として人工皮膚であるEpiSkin(SkinEthic社製)を用いた皮膚刺激性実験では、検体1の添加により刺激性は認められず、安全性が確認された。なお、この方法は細胞を用いる皮膚刺激性試験評価法として動物を使用しない方法として確立されている。 On the other hand, in a skin irritation experiment using EpiSkin (manufactured by SkinEthic), which is an artificial skin, as part of the safety test, no irritation was observed due to the addition of specimen 1, and safety was confirmed. This method has been established as a method for evaluating skin irritation using cells without using animals.
以下に、シソ種子と大豆種子を用いた植物活性化剤としての確認試験について述べる。
(試験例3)
Below, the confirmation test as a plant activator using perilla seed and soybean seed is described.
(Test Example 3)
長野県産のシソ種子と大豆種子を購入して用いた。シソ種子と大豆種子を検体1の1000倍希釈水溶液を十分に浸したガーゼを敷いたバットに置いた。これを30℃の培養器に入れて7日間培養し、芽の伸展を測定した。10個の種子の平均値を求めた。溶媒対照として水道水のみを用いた。同時に、対照にはHB−101(株式会社フローラ製)の1000倍液に浸して培養した。 Perilla seeds and soybean seeds from Nagano Prefecture were purchased and used. Perilla seeds and soybean seeds were placed on a vat covered with gauze sufficiently soaked in a 1000-fold diluted aqueous solution of Sample 1. This was placed in an incubator at 30 ° C. and cultured for 7 days, and bud spread was measured. The average value of 10 seeds was determined. Only tap water was used as a solvent control. At the same time, the culture was immersed in a 1000-fold solution of HB-101 (Flora Co., Ltd.) as a control.
その結果、シソ種子の芽は、溶媒対照を100%とした場合、検体1に浸した場合、146%、HB−101に浸漬した場合では131%となった。大豆種子では検体1に浸した場合、溶媒対照に比して150%と伸展した。一方、HB−101に浸漬した場合では溶媒対照の126%となった。これらの結果から検体1はHB−101よりも優れた植物活性化作用を呈すると結論された。 As a result, perilla seed buds were 146% when soaked in specimen 1, and 131% when soaked in HB-101, assuming that the solvent control was 100%. When soybean seeds were immersed in specimen 1, they extended to 150% compared to the solvent control. On the other hand, when immersed in HB-101, it was 126% of the solvent control. From these results, it was concluded that Specimen 1 exhibits a plant activating action superior to HB-101.
本発明で得られるデヒドロレチノール誘導体はケラチン産生作用を示し、かつ、副作用が少ないことから、国民のQOLを改善し、健康な労働人口を増加させ、かつ、医療費を削減できる。 Since the dehydroretinol derivative obtained by the present invention exhibits keratin production and has few side effects, it can improve the national QOL, increase the healthy working population, and reduce medical costs.
本発明で得られるデヒドロレチノール誘導体はケラチンを産生し皮膚細胞を改善する作用を有することから、化粧料としてアトピーや皮膚トラブルに悩む方の改善に貢献し、化粧料業界の発展に寄与する。 Since the dehydroretinol derivative obtained by the present invention has an action of producing keratin and improving skin cells, it contributes to the improvement of those suffering from atopy and skin trouble as a cosmetic and contributes to the development of the cosmetic industry.
本発明で得られるデヒドロレチノール誘導体は食品としても利用できることから、食品業界の発展に寄与する。 Since the dehydroretinol derivative obtained by the present invention can be used as a food, it contributes to the development of the food industry.
本発明で得られるデヒドロレチノール誘導体は植物活性剤として植物の伸展と成長、結実と収穫量を増加させ、砂漠の緑化対策や農業分野にも利用される。 The dehydroretinol derivative obtained in the present invention increases the elongation and growth of plants, fruit set and yield as a plant activator, and is also used in desert greening countermeasures and agricultural fields.
Claims (1)
A dehydroretinol derivative exhibiting a keratin producing action represented by the following formula (1).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016215863A JP6741965B2 (en) | 2016-11-04 | 2016-11-04 | Dehydroretinol derivative exhibiting keratin increasing action |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016215863A JP6741965B2 (en) | 2016-11-04 | 2016-11-04 | Dehydroretinol derivative exhibiting keratin increasing action |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018070559A true JP2018070559A (en) | 2018-05-10 |
| JP6741965B2 JP6741965B2 (en) | 2020-08-19 |
Family
ID=62113940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016215863A Active JP6741965B2 (en) | 2016-11-04 | 2016-11-04 | Dehydroretinol derivative exhibiting keratin increasing action |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6741965B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020138927A (en) * | 2019-02-28 | 2020-09-03 | 二村 芳弘 | A method for producing a hydroxypyran derivative exhibiting a vascular endothelial cell proliferation action and a step of culturing human oral cells. |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002501011A (en) * | 1998-01-26 | 2002-01-15 | ロレアル | Use of heterocyclic quaternary polyammonium polymers as protective agents for keratin fibers and cosmetic compositions |
| JP2015500630A (en) * | 2011-12-19 | 2015-01-08 | 国立大学法人京都大学 | Method for inducing differentiation from human pluripotent stem cells to intermediate mesoderm cells |
-
2016
- 2016-11-04 JP JP2016215863A patent/JP6741965B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002501011A (en) * | 1998-01-26 | 2002-01-15 | ロレアル | Use of heterocyclic quaternary polyammonium polymers as protective agents for keratin fibers and cosmetic compositions |
| JP2015500630A (en) * | 2011-12-19 | 2015-01-08 | 国立大学法人京都大学 | Method for inducing differentiation from human pluripotent stem cells to intermediate mesoderm cells |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020138927A (en) * | 2019-02-28 | 2020-09-03 | 二村 芳弘 | A method for producing a hydroxypyran derivative exhibiting a vascular endothelial cell proliferation action and a step of culturing human oral cells. |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6741965B2 (en) | 2020-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5583259B1 (en) | Novel derivative having collagen producing action and method for producing the same | |
| JP6369751B2 (en) | Curcumin derivative exhibiting keratin producing action and method for producing the same | |
| JP6388201B2 (en) | Carotenoid derivatives with cytokeratin increasing action | |
| JP5399468B2 (en) | Composition exhibiting lipolytic activity | |
| JP6436337B2 (en) | Quercetin derivative exhibiting elastin producing action and method for producing the same | |
| JP6741965B2 (en) | Dehydroretinol derivative exhibiting keratin increasing action | |
| JP6831049B2 (en) | Method for producing a grunge fluorolic acid derivative exhibiting an NF-κB inhibitory effect | |
| JP6802537B1 (en) | Dopaquinone derivatives exhibiting hemidesmosome activating action and methods for producing them | |
| JP2016088857A (en) | Nervonic acid derivative exhibiting amyloid formation inhibitory action and method for producing the derivative | |
| JP2014033630A (en) | Method for producing edelweiss new root fermentation essence exerting collagen increasing effect similar to placenta | |
| JP2016088858A (en) | Resveratrol derivative that generates hydrogen and exhibits keratin producing action and method for producing the derivative | |
| JP6490997B2 (en) | Jewenol A derivative exhibiting ATP increasing action and method for producing the same | |
| JP6546048B2 (en) | Phenylpropanoid derivative exhibiting glycolytic activation activity and method for producing the same | |
| JP6010073B2 (en) | Resveratrol derivative producing hydrogen gas and exhibiting keratin production action and method for producing the same | |
| JP5403638B2 (en) | Composition exhibiting collagen producing action | |
| JP6891364B2 (en) | Fumaric acid derivative exhibiting gene repair action | |
| JP7079920B2 (en) | A method for producing a hydroxypyran derivative exhibiting a proliferative effect on vascular endothelial cells and a method for culturing human oral cells. | |
| JP6606635B2 (en) | Carotenoid derivatives with cytokeratin increasing action | |
| JP6380840B2 (en) | Carotenoid derivatives exhibiting preadipocyte growth inhibitory action | |
| JP6738524B2 (en) | Leucocyanidin derivatives exhibiting activating effect on oxidative phosphorylation | |
| JP2018070558A (en) | Glycerol derivative showing gene restoration action | |
| JP6821909B2 (en) | Quinoline derivative exhibiting human estrogen receptor activating action | |
| JP2017052731A (en) | Flavonoid derivative showing the activation action of skin stem cell | |
| JP6471974B2 (en) | Indole derivatives exhibiting NF-κB class II inhibitory action and method for producing the same | |
| JP2021088535A (en) | Eriodictyol derivative exhibiting melanocyte proliferation-suppressing action via melanocyte-stimulating hormone receptor-suppressing action |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190724 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200630 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200707 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6741965 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |